ACET
Price
$0.72
Change
+$0.01 (+1.41%)
Updated
Sep 5 closing price
Capitalization
59.97M
60 days until earnings call
SUPN
Price
$46.00
Change
+$0.57 (+1.25%)
Updated
Sep 5 closing price
Capitalization
2.58B
66 days until earnings call
Interact to see
Advertisement

ACET vs SUPN

Header iconACET vs SUPN Comparison
Open Charts ACET vs SUPNBanner chart's image
Adicet Bio
Price$0.72
Change+$0.01 (+1.41%)
Volume$360.04K
Capitalization59.97M
Supernus Pharmaceuticals
Price$46.00
Change+$0.57 (+1.25%)
Volume$657.58K
Capitalization2.58B
ACET vs SUPN Comparison Chart in %
Loading...
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ACET vs. SUPN commentary
Sep 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACET is a Hold and SUPN is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 07, 2025
Stock price -- (ACET: $0.72 vs. SUPN: $46.00)
Brand notoriety: ACET and SUPN are both not notable
ACET represents the Biotechnology, while SUPN is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: ACET: 72% vs. SUPN: 77%
Market capitalization -- ACET: $59.97M vs. SUPN: $2.58B
ACET [@Biotechnology] is valued at $59.97M. SUPN’s [@Pharmaceuticals: Generic] market capitalization is $2.58B. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $67.95B to $0. The average market capitalization across the [@Biotechnology] industry is $1.91B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.94B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACET’s FA Score shows that 2 FA rating(s) are green whileSUPN’s FA Score has 0 green FA rating(s).

  • ACET’s FA Score: 2 green, 3 red.
  • SUPN’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACET and SUPN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACET’s TA Score shows that 6 TA indicator(s) are bullish while SUPN’s TA Score has 3 bullish TA indicator(s).

  • ACET’s TA Score: 6 bullish, 3 bearish.
  • SUPN’s TA Score: 3 bullish, 3 bearish.
According to our system of comparison, ACET is a better buy in the short-term than SUPN.

Price Growth

ACET (@Biotechnology) experienced а +0.04% price change this week, while SUPN (@Pharmaceuticals: Generic) price change was +1.95% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.52%. For the same industry, the average monthly price growth was +14.48%, and the average quarterly price growth was +31.71%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +0.10%. For the same industry, the average monthly price growth was +12.13%, and the average quarterly price growth was +87.01%.

Reported Earning Dates

ACET is expected to report earnings on Nov 05, 2025.

SUPN is expected to report earnings on Nov 11, 2025.

Industries' Descriptions

@Biotechnology (+2.52% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (+0.10% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SUPN($2.58B) has a higher market cap than ACET($60M). SUPN YTD gains are higher at: 27.212 vs. ACET (-25.125). SUPN has higher annual earnings (EBITDA): 174M vs. ACET (-112.08M). SUPN has more cash in the bank: 523M vs. ACET (125M). ACET has less debt than SUPN: ACET (15.4M) vs SUPN (31.8M). SUPN has higher revenues than ACET: SUPN (665M) vs ACET (0).
ACETSUPNACET / SUPN
Capitalization60M2.58B2%
EBITDA-112.08M174M-64%
Gain YTD-25.12527.212-92%
P/E RatioN/A40.00-
Revenue0665M-
Total Cash125M523M24%
Total Debt15.4M31.8M48%
FUNDAMENTALS RATINGS
ACET vs SUPN: Fundamental Ratings
ACET
SUPN
OUTLOOK RATING
1..100
418
VALUATION
overvalued / fair valued / undervalued
1..100
28
Undervalued
78
Overvalued
PROFIT vs RISK RATING
1..100
10039
SMR RATING
1..100
9880
PRICE GROWTH RATING
1..100
8139
P/E GROWTH RATING
1..100
19100
SEASONALITY SCORE
1..100
7550

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACET's Valuation (28) in the Medical Distributors industry is somewhat better than the same rating for SUPN (78) in the Pharmaceuticals Other industry. This means that ACET’s stock grew somewhat faster than SUPN’s over the last 12 months.

SUPN's Profit vs Risk Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for ACET (100) in the Medical Distributors industry. This means that SUPN’s stock grew somewhat faster than ACET’s over the last 12 months.

SUPN's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as ACET (98) in the Medical Distributors industry. This means that SUPN’s stock grew similarly to ACET’s over the last 12 months.

SUPN's Price Growth Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for ACET (81) in the Medical Distributors industry. This means that SUPN’s stock grew somewhat faster than ACET’s over the last 12 months.

ACET's P/E Growth Rating (19) in the Medical Distributors industry is significantly better than the same rating for SUPN (100) in the Pharmaceuticals Other industry. This means that ACET’s stock grew significantly faster than SUPN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACETSUPN
RSI
ODDS (%)
Bullish Trend 2 days ago
85%
Bearish Trend 2 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
89%
N/A
Momentum
ODDS (%)
Bullish Trend 2 days ago
78%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
64%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
88%
Bullish Trend 2 days ago
72%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 10 days ago
82%
Bullish Trend 2 days ago
75%
Declines
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 5 days ago
64%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
70%
View a ticker or compare two or three
Interact to see
Advertisement
ACET
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SUPN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MILIF0.320.01
+3.91%
MILITARY METALS CORP.
FNRN12.070.07
+0.58%
First Northern Community Bancorp
PNDZF138.50N/A
N/A
Pandora A/S
EMCUF12.80N/A
N/A
EMBRACE CHANGE ACQUISITION CORP.
TAVHY23.35-0.41
-1.72%
Tav Havalimanlari Holding AS

ACET and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACET has been loosely correlated with SYRE. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ACET jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACET
1D Price
Change %
ACET100%
+1.00%
SYRE - ACET
43%
Loosely correlated
+0.06%
IPSC - ACET
43%
Loosely correlated
+5.41%
OGI - ACET
41%
Loosely correlated
+2.48%
RGNX - ACET
41%
Loosely correlated
+3.08%
ARWR - ACET
39%
Loosely correlated
+3.84%
More